🇺🇸 FDA

Company profile · Sponsor

Tonix

Tonix Pharmaceuticals Holding

TNXP · NYSE pharma BERKELEY HEIGHTS, NJ, USA
Pipeline
24
Drugs
3
Patents
8

Quick answer

Tonix (TNXP) is a pharma company. headquartered in BERKELEY HEIGHTS, NJ, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 3 drugs, and 8 patents to this profile..

Company facts

Ticker TNXP
Exchange NYSE
Company type pharma
Headquarters BERKELEY HEIGHTS, NJ, USA
SEC CIK 0001430306

Pipeline (24)

Search pipeline →

  1. TNX-102 SL

    Tonix

    Primary Fibromyalgia

    phase 3 small molecule completed

    1 trial

  2. TNX-102 SL

    Tonix

    PTSD

    phase 3 small molecule terminated

    6 trials

  3. TNX-102 SL

    Tonix

    Fibromyalgia

    phase 3 small molecule completed

    2 trials

  4. TNX-102 SL 2.8mg

    Tonix

    Primary Fibromyalgia

    phase 3 small molecule completed

    1 trial

  5. TNX-102 SL 5.6 mg

    Tonix

    PTSD

    phase 3 small molecule completed

    1 trial

  6. TNX-102 SL Tablet 2.8 mg

    Tonix

    Primary Fibromyalgia

    phase 3 small molecule completed

    1 trial

  7. TNX-102 SL Tablet, 2.8 mg

    Tonix

    Fibromyalgia

    phase 3 small molecule terminated

    1 trial

  8. TNX-102 SL Tablet, 2.8mg

    Tonix

    Fibromyalgia

    phase 3 small molecule completed

    1 trial

  9. TNX-102 SL Tablet, 5.6 mg

    Tonix

    Fibromyalgia

    phase 3 small molecule completed

    1 trial

  10. Cyclobenzaprine HCl

    Tonix

    Acute Stress Reaction

    phase 2 small molecule active

    1 trial

  11. TNX-102 SL

    Tonix

    Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection

    phase 2 small molecule completed

    1 trial

  12. TNX-1300

    Tonix

    Cocaine Intoxication

    phase 2 small molecule terminated

    1 trial

  13. TNX-1500

    Tonix

    Kidney Transplant

    phase 2 small molecule active

    1 trial

  14. TNX-1900

    Tonix

    Chronic Migraine

    phase 2 small molecule completed

    1 trial

  15. TNX-201

    Tonix

    Tension-Type Headache

    phase 2 small molecule completed

    1 trial

  16. TNX-601 ER

    Tonix

    Depression

    phase 2 small molecule completed

    1 trial

  17. Imaging procedure to measure the distribution of a newly developed radiolabeled ligand for the oxytocin receptor

    Tonix

    Pain, Face

    phase 1 small molecule completed

    1 trial

  18. Intranasal Oxytocin (IN-OXT)

    Tonix

    Vasopressin Deficiency

    phase 1 small molecule active

    1 trial

  19. SL TNX-102 2.4 mg at pH 3.5

    Tonix

    Healthy Adults

    phase 1 small molecule completed

    1 trial

  20. SL TNX-102 at 2.4 mg

    Tonix

    Healthy Adults

    phase 1 small molecule completed

    1 trial

  21. TNX-102 SL

    Tonix

    Healthy Subjects (HS)

    phase 1 small molecule completed

    1 trial

  22. TNX-102 SL

    Tonix

    Healthy Subjects

    phase 1 small molecule completed

    1 trial

  23. TNX-102 SL 5.6 mg

    Tonix

    Healthy Subjects

    phase 1 small molecule completed

    1 trial

  24. TNX-102 SL Tablet

    Tonix

    Pharmakokinetic

    phase 1 small molecule active

    1 trial

Drugs (3)

Search drugs →

  1. cyclobenzaprine hydrochloride

    CYCLOBENZAPRINE HYDROCHLORIDE

    ORAL approved

  2. sumatriptan

    SUMATRIPTAN GALPHARM

    ORAL approved

  3. sumatriptan succinate

    SUMATRIPTAN SUCCINATE

    IONTOPHORESIS approved

Patents (8)

Search patents →

  1. US 12383733

    Iontophoresis-based patch type medicine absorption device

    Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12365879

    Synthetic chimeric poxviruses

    Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12304901

    Selective ligands for tau aggregates

    Expires Mon May 15 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12156864

    Analogs of cyclobenzaprine and amitryptilene

    Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12156897

    Magnesium-containing oxytocin formulations and methods of use

    Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12097183

    Pharmaceutical composition for treating migraine

    Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12090139

    Formulations comprising triptan compounds

    Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11998516

    Methods and compositions for treating depression using cyclobenzaprine

    Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Tonix?

Tonix (TNXP) is a pharma company. headquartered in BERKELEY HEIGHTS, NJ, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 3 drugs, and 8 patents to this profile..

What pipeline programs does Tonix sponsor?

We track 24 ClinicalTrials.gov-linked programs for Tonix, including TNX-102 SL and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Tonix company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.